PortfoliosLab logo
ACAD vs. ABT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ACAD and ABT is 0.54, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

ACAD vs. ABT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and Abbott Laboratories (ABT). The values are adjusted to include any dividend payments, if applicable.

200.00%400.00%600.00%800.00%1,000.00%December2025FebruaryMarchAprilMay
152.69%
996.74%
ACAD
ABT

Key characteristics

Sharpe Ratio

ACAD:

-0.02

ABT:

1.48

Sortino Ratio

ACAD:

0.33

ABT:

2.09

Omega Ratio

ACAD:

1.04

ABT:

1.27

Calmar Ratio

ACAD:

-0.01

ABT:

1.15

Martin Ratio

ACAD:

-0.03

ABT:

7.00

Ulcer Index

ACAD:

15.42%

ABT:

4.20%

Daily Std Dev

ACAD:

47.43%

ABT:

20.59%

Max Drawdown

ACAD:

-96.29%

ABT:

-45.66%

Current Drawdown

ACAD:

-70.30%

ABT:

-3.99%

Fundamentals

Market Cap

ACAD:

$2.53B

ABT:

$230.70B

EPS

ACAD:

$1.36

ABT:

$7.70

PE Ratio

ACAD:

11.13

ABT:

17.22

PEG Ratio

ACAD:

-0.42

ABT:

4.17

PS Ratio

ACAD:

2.64

ABT:

5.33

PB Ratio

ACAD:

3.39

ABT:

4.69

Total Revenue (TTM)

ACAD:

$751.97M

ABT:

$42.34B

Gross Profit (TTM)

ACAD:

$693.08M

ABT:

$23.67B

EBITDA (TTM)

ACAD:

$76.85M

ABT:

$11.20B

Returns By Period

In the year-to-date period, ACAD achieves a -7.74% return, which is significantly lower than ABT's 19.64% return. Over the past 10 years, ACAD has underperformed ABT with an annualized return of -7.88%, while ABT has yielded a comparatively higher 13.13% annualized return.


ACAD

YTD

-7.74%

1M

20.07%

6M

-1.57%

1Y

-1.17%

5Y*

-19.76%

10Y*

-7.88%

ABT

YTD

19.64%

1M

8.61%

6M

17.37%

1Y

30.26%

5Y*

9.37%

10Y*

13.13%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ACAD vs. ABT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD
The Risk-Adjusted Performance Rank of ACAD is 4949
Overall Rank
The Sharpe Ratio Rank of ACAD is 5050
Sharpe Ratio Rank
The Sortino Ratio Rank of ACAD is 4646
Sortino Ratio Rank
The Omega Ratio Rank of ACAD is 4646
Omega Ratio Rank
The Calmar Ratio Rank of ACAD is 5252
Calmar Ratio Rank
The Martin Ratio Rank of ACAD is 5151
Martin Ratio Rank

ABT
The Risk-Adjusted Performance Rank of ABT is 8888
Overall Rank
The Sharpe Ratio Rank of ABT is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of ABT is 8787
Sortino Ratio Rank
The Omega Ratio Rank of ABT is 8585
Omega Ratio Rank
The Calmar Ratio Rank of ABT is 8686
Calmar Ratio Rank
The Martin Ratio Rank of ABT is 9191
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ACAD vs. ABT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ACAD Sharpe Ratio is -0.02, which is lower than the ABT Sharpe Ratio of 1.48. The chart below compares the historical Sharpe Ratios of ACAD and ABT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.50December2025FebruaryMarchAprilMay
-0.02
1.48
ACAD
ABT

Dividends

ACAD vs. ABT - Dividend Comparison

ACAD has not paid dividends to shareholders, while ABT's dividend yield for the trailing twelve months is around 1.70%.


TTM20242023202220212020201920182017201620152014
ACAD
ACADIA Pharmaceuticals Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
ABT
Abbott Laboratories
1.70%1.95%1.85%1.71%1.28%1.32%1.47%1.55%1.86%2.71%2.14%1.95%

Drawdowns

ACAD vs. ABT - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, which is greater than ABT's maximum drawdown of -45.66%. Use the drawdown chart below to compare losses from any high point for ACAD and ABT. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-70.30%
-3.99%
ACAD
ABT

Volatility

ACAD vs. ABT - Volatility Comparison

ACADIA Pharmaceuticals Inc. (ACAD) has a higher volatility of 17.75% compared to Abbott Laboratories (ABT) at 5.53%. This indicates that ACAD's price experiences larger fluctuations and is considered to be riskier than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%December2025FebruaryMarchAprilMay
17.75%
5.53%
ACAD
ABT

Financials

ACAD vs. ABT - Financials Comparison

This section allows you to compare key financial metrics between ACADIA Pharmaceuticals Inc. and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B20212022202320242025
259.60M
10.36B
(ACAD) Total Revenue
(ABT) Total Revenue
Values in USD except per share items

ACAD vs. ABT - Profitability Comparison

The chart below illustrates the profitability comparison between ACADIA Pharmaceuticals Inc. and Abbott Laboratories over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%60.0%70.0%80.0%90.0%100.0%20212022202320242025
91.6%
56.9%
(ACAD) Gross Margin
(ABT) Gross Margin
ACAD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, ACADIA Pharmaceuticals Inc. reported a gross profit of 237.80M and revenue of 259.60M. Therefore, the gross margin over that period was 91.6%.

ABT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Abbott Laboratories reported a gross profit of 5.89B and revenue of 10.36B. Therefore, the gross margin over that period was 56.9%.

ACAD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, ACADIA Pharmaceuticals Inc. reported an operating income of 153.50M and revenue of 259.60M, resulting in an operating margin of 59.1%.

ABT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Abbott Laboratories reported an operating income of 1.69B and revenue of 10.36B, resulting in an operating margin of 16.3%.

ACAD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, ACADIA Pharmaceuticals Inc. reported a net income of 143.74M and revenue of 259.60M, resulting in a net margin of 55.4%.

ABT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Abbott Laboratories reported a net income of 1.33B and revenue of 10.36B, resulting in a net margin of 12.8%.